tanespimycin

Small moleculeexperimental

Tanespimycin is a derivative of the antibiotic geldanamycin that is being studied in the treatment of cancer, specifically in younger patients with certain types of leukemia or solid tumors, especially kidney tumors. — Wikipedia

Clinical trial activity

51 trials · 25 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 1998 (NCT00003969)

Timeline

1990s

Jan 1, 1998
Earliest Phase 1 Sponsor(trial)

2000s

Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Jan 1, 2008
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Heat shock protein HSP90INHIBITOR
Heat shock protein HSP90 inhibitor
Disrupts the Hsp90 chaperone complex.
Binds to a highly conserved 25 kDa N-terminal domain of Hsp90, a binding site for ATP
- Heat shock protein HSP 90-alpha (HSP90AA1) ↗
- Heat shock protein HSP 90-beta (HSP90AB1) ↗
- Heat shock protein HSP 90-alpha
- Heat shock protein HSP 90-beta

Chemistry & pharmacology

Loading structure…

SMILES

C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2

Mol. weight: 587.71 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

17aag
17aag
17aag
17-aag
17 allylamino-17-demethoxygeldanamycin
17 allylamino-17-demethoxygeldanamycin
17-(allylamino)-17-demethoxygeldanamycin
17-(allylamino)-17-demethoxy-geldanamycin
17-allylamino-17-demethoxygeldanamycin
17-allylamino-17-demethoxygeldanamycin hydroquinone
17-allylamino-17-demethoxygeldanamycin hydroquinone salt
17-allylaminogeldanamycin
17-allyl-aminogeldanamycin
17-allylamino-geldanamycin
((4e,6e,8s,9s,10e,12s,13r,14s,16r)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo(16.3.1)docosa-4,6,10,18,21-pentaen-9-yl) carbamate
abi-010
bms-722782
bms-722782
cnf1010
cnf1010
cnf1010
ipi493
ipi 493
ipi-493
ipi-493
ipi-493
ipi-493
ipi504
ipi 504
ipi 504
ipi 504
ipi-504
ipi-504
ipi-504
ipi-504
nsc 330507
nsc-330507
retaspimycin
retaspimycin
retaspimycin
retaspimycin hcl
retaspimycin hcl
retaspimycin hydrochloride
retaspimycin hydrochloride
retaspimycin hydrochloride
tanespimycin
tanespimycin
tanespimycin
tanespimycin
tanespimycin

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00820768	Phase 1	Apr 1, 2012	Celgene, Mayo Clinic
NCT01427946	Phase 1/Phase 2 (Phase 2)	Jul 1, 2011	Infinity Pharmaceuticals, Inc.
NCT01362400	Phase 2	May 1, 2011	Infinity Pharmaceuticals, Inc.
NCT01228435	Phase 2	Oct 1, 2010	Harvard University, Infinity Pharmaceuticals, Inc.
NCT01193491	Phase 1	Jun 1, 2010	Infinity Pharmaceuticals, Inc.
NCT00969917	Phase 2	Jan 1, 2010	Infinity Pharmaceuticals, Inc.
NCT00817362	Phase 2	Mar 1, 2009	Infinity Pharmaceuticals, Inc.
NCT00688766	Phase 3	Aug 1, 2008	AstraZeneca, Harvard University, Infinity Pharmaceuticals, Inc., MedImmune
NCT00724425	Phase 1	Jul 1, 2008	Infinity Pharmaceuticals, Inc.
NCT00627627	Phase 1/Phase 2 (Phase 2)	Apr 1, 2008	MedImmune
NCT00577889	Phase 2	Mar 1, 2008	Mayo Clinic, National Cancer Institute (NCI)
NCT00546780	Phase 3	Feb 1, 2008	Bristol-Myers Squibb
NCT00627419	Phase 2	Feb 1, 2008	Infinity Pharmaceuticals, Inc.
NCT00606814	Phase 1	Dec 1, 2007	Cornell University, Infinity Pharmaceuticals, Inc.
NCT00564928	Phase 2	Nov 1, 2007	Harvard University, Infinity Pharmaceuticals, Inc.
NCT00093496	Phase 2	Oct 1, 2007	Mayo Clinic, National Cancer Institute (NCI)
NCT00514371	Phase 2/Phase 3 (Phase 3)	Aug 1, 2007	Bristol-Myers Squibb
NCT00431015	Phase 1/Phase 2 (Phase 2)	Jan 1, 2007	Harvard University, Infinity Pharmaceuticals, Inc.
NCT00779428	Phase 2	Jul 1, 2006	Bristol-Myers Squibb
NCT00354185	Phase 1	May 1, 2006	National Cancer Institute (NCI), University of Wisconsin

Showing 20 of 51 trials

Page 1 / 3

Organizations

Research & Development (25)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
National Cancer Institute (NCI)	Government	29	22	2	1999
Infinity Pharmaceuticals, Inc.	For profit	14	13	3	2005
Mayo Clinic	Academic/Hospital	9	1	2	1999
Cornell University	Academic/Hospital	7	2	2	1999
Harvard University	Academic/Hospital	6	1	3	2005
Bristol-Myers Squibb	For profit	4	4	2	2005
Wayne State University	Academic/Hospital	3	1	2	2003
Cancer Research UK	Academic/Hospital	2	2	2	1998
MedImmune	For profit	2	1	2	2008
Ohio State University	Academic/Hospital	2	0	1	2005
AstraZeneca	For profit	1	0	1	2008
Biogen	For profit	1	1	1	2005
Celgene	For profit	1	1	1	2012
Johns Hopkins University	Academic/Hospital	1	0	1	2005
National Institutes of Health (NIH)	Government	1	1	1	2006
New York Medical College	Academic/Hospital	1	0	1	2005
Royal Marsden Hospital NHS Trust	Academic/Hospital	1	0	1	1998
Rutgers University	Academic/Hospital	1	0	1	2005
University of California, Los Angeles	Academic/Hospital	1	1	1	2004
University of Cambridge	Academic/Hospital	1	0	1	2005

25 organizations

Page 1 / 2